Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Augmentation With Cannabidiol in First Episode Psychosis
NCT06778564Phase 3Recruiting
- Sponsor
- University of Oxford
- Start
- Oct 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in psychosis comparing Cannabidiol (CBD) with Placebo (2 arms). Primary endpoint: Positive and Negative Syndrome Scale at 6 weeks. Started Oct 2026; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
psychosis
Beyond the preview
Go deeper on NCT06778564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06778564.